Email this article ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution
- Authors: Poddubnaya I.V.1, Al-Radi L.S.2,3, Byalik T.E.4, Kaplanov K.D.5, Molostvova V.Z.6, Nikitin E.A.7,8, Pospelova T.I.9, Ptushkin V.V.10,8, Samoilova O.S.11, Stadnik E.A.12, Tumyan G.S.13
-
Affiliations:
- Federal State Budgetary Educational Institution of Higher Professional Education “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia
- Federal State Budgetary Institution National Medical Research Center for Hematology
- Ministry of Health of Russia
- Federal State Budgetary Institution National Medical Research Center for Oncology named after N.N. Blokhina Ministry of Health of Russia
- Volgograd Regional Clinical Oncology Center
- KGBUZ Regional Clinical Hospital No. 1 named after prof. S.I. Sergeeva Ministry of Health of the Khabarovsk Territory
- GBUZ “City Clinical Hospital named after S.P. Botkin ”, Moscow Department of Health
- Moscow City Hematology Center
- FSBEI HE "Novosibirsk State Medical University" of the Ministry of Health of Russia
- City Clinical Hospital named after S.P. Botkin, Moscow Department of Health
- GBUZ NO Nizhny Novgorod Regional Clinical Hospital named after N. A. Semashko
- FSBEI HE First St. Petersburg State Medical University named after Acad. I.P. Pavlova Ministry of Health of Russia
- Federal State Budgetary Institution National Medical Research Center for Oncology named after N.N. Blokhina Ministry of Health of Russia
- Issue: Vol 22, No 1 (2020)
- Pages: 31-33
- Section: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/34167
- DOI: https://doi.org/10.26442/18151434.2020.1.200090
- ID: 34167
Cite item
Full Text
Abstract
Over the past decade, we have seen a significant change in modern approaches in the first-line treatment of chronic lymphocytic leukemia (CLL). The CLL-10 study data established the FCR regimen as the treatment of choice for younger patients with limited comorbidities, while for patients older than 65 years, the BR regimen is more often considered as less toxic one. According to published data, 46% of patients with newly diagnosed CLL have comorbidities. Moreover, high-risk patients with del(17p) and/or TP53 mutation do not have response on immunochemotherapy (ICT) most often. Thus, about 1/2 of the patients cannot be treated or will not respond to standard ICT regimens. Targeted therapy with Bruton’s tyrosine kinase (BTK) inhibitors is an important option of the first-line treatment of patients with CLL. Acalabrutinib is a highly selective second-generation BTK inhibitor that does not inhibit EGFR, ITK or TEC targets. Acalabrutinib in combination with obinutuzumab or as monotherapy can be considered as a highly effective and safe option of the first line of CLL therapy. Based on the hight selectivity of the agent, acalabrutinib can be considered as the preferable option for patients who are not eligible for ICT, including patients with commodities, such as cardiovascular diseases or risk factors for their development.
Full Text
##article.viewOnOriginalSite##About the authors
Irina V. Poddubnaya
Federal State Budgetary Educational Institution of Higher Professional Education “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia
Author for correspondence.
Email: or@hpmp.ru
academician of the Russian Academy of Sciences, doctor of medical sciences, professor
Russian Federation, MoscowLyubov S. Al-Radi
Federal State Budgetary Institution National Medical Research Center for Hematology; Ministry of Health of Russia
Email: or@hpmp.ru
candidate of medical sciences
Russian Federation, MoscowTatyana E. Byalik
Federal State Budgetary Institution National Medical Research Center for Oncology named after N.N. Blokhina Ministry of Health of Russia
Email: or@hpmp.ru
candidate of medical sciences
Russian Federation, MoscowKamil D. Kaplanov
Volgograd Regional Clinical Oncology Center
Email: or@hpmp.ru
Candidate of Medical Sciences
Russian Federation, VolgogradValentina Z. Molostvova
KGBUZ Regional Clinical Hospital No. 1 named after prof. S.I. Sergeeva Ministry of Health of the Khabarovsk Territory
Email: or@hpmp.ru
Candidate of Medical Sciences
Russian Federation, KhabarovskEvgeniy A. Nikitin
GBUZ “City Clinical Hospital named after S.P. Botkin ”, Moscow Department of Health; Moscow City Hematology Center
Email: or@hpmp.ru
Doctor of Medical Sciences, Professor
Russian Federation, MoscowTatyana I. Pospelova
FSBEI HE "Novosibirsk State Medical University" of the Ministry of Health of Russia
Email: or@hpmp.ru
Doctor of Medical Sciences, Professor
Russian Federation, NovosibirskVadim V. Ptushkin
City Clinical Hospital named after S.P. Botkin, Moscow Department of Health; Moscow City Hematology Center
Email: or@hpmp.ru
Doctor of Medical Sciences, Professor
Russian Federation, MoscowOlga S. Samoilova
GBUZ NO Nizhny Novgorod Regional Clinical Hospital named after N. A. Semashko
Email: or@hpmp.ru
Candidate of Medical Sciences
Russian Federation, Nizhny NovgorodElena A. Stadnik
FSBEI HE First St. Petersburg State Medical University named after Acad. I.P. Pavlova Ministry of Health of Russia
Email: or@hpmp.ru
Candidate of Medical Sciences
Russian Federation, St. PetersburgGayane S. Tumyan
Federal State Budgetary Institution National Medical Research Center for Oncology named after N.N. Blokhina Ministry of Health of Russia
Email: or@hpmp.ru
Doctor of Medical Sciences
Russian Federation, MoscowReferences
- Thompson PA, Tam CS, O’Brien SM et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 2016; 127: 303.
- Nitin Jain et al. Approaches to Chronic Lymphocytic c Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options. N Jain 2018 ASCO Educational book; p. 580–91.
- Woyach JA. Acalabrutinib with obinutuzumab in treatment-naïve and relapse/refractory chronic leukemia: 3-year follow-up. EHA 2019 Abstract PF377
- Eichhorst B et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016; 17: 928–42.
- Gribben JG. How I treat CLL up front. Blood 2010; 115 (2): 187–97.
- Weide R et al. Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995–2017. Blood 2018; 132 (Suppl. 1): 4823.
- Sanam Shafaattalab et al. Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes. Stem Cell Reports 2019; 12; 996–1006.
- Wu et al. Acalabrutinib (ACP-196): a selective second generation BTK inhibitor. J Hematol Oncol 2016; 9: 21.
- McMullen JR et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood 2014; 124: 3829–30.
- Mato et al. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. Am J Hematol 2018; 93: 1394–401.
- Byrd JC et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 2016; 374 (4): 323–32.
- Covey T et al. Abstract 2596: ACP-196: a novel covalent Bruton’s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Cancer Res 2015; 75 (15 Suppl.): 2596.
- Sharman JP et al. ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). Abstract 31 at: American Society of Hematology 2019 Annual Meeting and Exposition.
- https://clinicaltrials.gov/ct2/show/NCT02475681?term=acalabrutinib&draw=6&rank=47
